Alnylam Pharmaceuticals (ALNY) revenue breakdown
By product, Net product revenues is the largest at 80% of fiscal 2025 revenue, growing 46% a year over 4 years.
Revenue by product
Fiscal years, as Alnylam Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $3.7B.
| Products | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|
| Net product revenues | $662M | $894M | $1.2B | $1.6B | $3.0B | 80% |
| Net revenues from collaborations | $181M | $135M | $546M | $510M | $553M | 15% |
| Royalty revenue | $1M | $8M | $41M | $92M | $174M | 5% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ALNY.
Open ALNY in InvestinglyQuestions
Where does Alnylam Pharmaceuticals make its money?
In fiscal 2025, by product: Net product revenues $3.0B, Net revenues from collaborations $553M, Royalty revenue $174M.
From Alnylam Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.